Q-omics provides the consensus-scored MIR3150BHG profile across patient tissues and cancer cell-line models. MIR3150BHG expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR3150BHG is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MIR3150BHG RNA expression shows 12,627 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where MIR3150BHG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3150BHG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3150BHG survival associations across molecular data types. MIR3150BHG RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3150BHG RNA expression–survival associations across cancer types. High MIR3150BHG expression shows unfavorable associations in UVM, OV, LIHC, LGG and MESO, but favorable associations in CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for MIR3150BHG RNA expression.
This table summarizes MIR3150BHG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3150BHG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3150BHG shows lower tumor expression in COAD and higher tumor expression in BRCA, HNSC, LIHC, LUAD and BLCA. The COAD box plot shows higher MIR3150BHG RNA expression in normal versus tumor tissue (log2 FC = −0.874, t-test p < 0.001).
This table shows molecular features associated with MIR3150BHG in patient tissues and cancer cell lines. In patient samples, MIR3150BHG shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
